These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 27665470

  • 1. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.
    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, Jary M, Simon P, Pivot X, Blay JY, Limat S.
    Clin Drug Investig; 2017 Jan; 37(1):85-94. PubMed ID: 27665470
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD, Huse DM.
    J Med Econ; 2010 Jan; 13(4):681-90. PubMed ID: 21067355
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
    Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A.
    Clin Drug Investig; 2017 Jun; 37(6):525-533. PubMed ID: 28361439
    [Abstract] [Full Text] [Related]

  • 7. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
    Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL.
    Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
    Ahlman H, Nilsson O, Nilsson B.
    Lakartidningen; 2008 Feb; 106(50-51):3424-9. PubMed ID: 20180446
    [No Abstract] [Full Text] [Related]

  • 10. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour.
    Chabot I, LeLorier J, Blackstein ME.
    Eur J Cancer; 2008 May; 44(7):972-7. PubMed ID: 18372169
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)].
    Nishida T, Wakasugi M, Ueshima S.
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1330-5. PubMed ID: 22996768
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
    Paz-Ares L, del Muro JG, Grande E, Díaz S.
    J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
    [Abstract] [Full Text] [Related]

  • 20. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.